Frank Rimerman Advisors LLC Makes New Investment in Zimmer Biomet Holdings, Inc. $ZBH

Frank Rimerman Advisors LLC purchased a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 2,523 shares of the medical equipment provider’s stock, valued at approximately $230,000.

Other hedge funds have also recently modified their holdings of the company. Accent Capital Management LLC bought a new position in shares of Zimmer Biomet during the first quarter valued at approximately $35,000. Zions Bancorporation National Association UT purchased a new stake in Zimmer Biomet during the first quarter worth $48,000. Hilltop National Bank purchased a new stake in Zimmer Biomet during the second quarter worth $42,000. Brooklyn Investment Group boosted its position in Zimmer Biomet by 45.9% during the 1st quarter. Brooklyn Investment Group now owns 461 shares of the medical equipment provider’s stock valued at $52,000 after acquiring an additional 145 shares in the last quarter. Finally, True Wealth Design LLC increased its holdings in shares of Zimmer Biomet by 875.0% in the 2nd quarter. True Wealth Design LLC now owns 468 shares of the medical equipment provider’s stock valued at $43,000 after acquiring an additional 420 shares during the period. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Up 3.4%

Zimmer Biomet stock opened at $92.12 on Friday. The business’s 50-day simple moving average is $97.17 and its two-hundred day simple moving average is $96.75. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.96 and a current ratio of 1.87. The company has a market cap of $18.26 billion, a PE ratio of 22.41, a PEG ratio of 2.29 and a beta of 0.67. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $85.33 and a fifty-two week high of $114.44.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. The firm had revenue of $2 billion for the quarter, compared to analyst estimates of $2.01 billion. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The business’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.74 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th were given a dividend of $0.24 per share. The ex-dividend date was Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is 23.76%.

Insider Activity

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the stock in a transaction on Monday, September 8th. The shares were sold at an average price of $104.15, for a total transaction of $156,225.00. Following the transaction, the senior vice president directly owned 6,833 shares of the company’s stock, valued at $711,656.95. This trade represents a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.39% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of brokerages recently weighed in on ZBH. Barclays decreased their price objective on Zimmer Biomet from $112.00 to $105.00 and set an “underweight” rating for the company in a research note on Wednesday, November 5th. BTIG Research reduced their target price on shares of Zimmer Biomet from $122.00 to $112.00 and set a “buy” rating for the company in a report on Wednesday, November 5th. Raymond James Financial increased their price target on shares of Zimmer Biomet from $104.00 to $113.00 and gave the company an “outperform” rating in a research report on Friday, August 8th. Rothschild Redb raised shares of Zimmer Biomet to a “strong-buy” rating in a research report on Thursday, September 18th. Finally, Wall Street Zen lowered shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a research note on Sunday, November 16th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $109.00.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.